NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Regulatoryobicetrapibobicetrapib/ezetimibePositive

AI Analysis

Summary

NewAmsterdam Pharma announced regulatory decisions on obicetrapib and its fixed-dose combination with ezetimibe are expected in the second half of 2026 from EMA, UK, and Switzerland authorities, with potential launches by Menarini in Germany and the UK by 4Q26 pending positive outcomes.

Outcome Details

Regulatory decisions from EMA, UK, and Switzerland expected in 2H26

Importance:6/10

Sentiment:

0.30

regulatory_updateEMAUK_regulatorySwitzerland_regulatoryproduct_launchfixed_dose_combination

Related Companies

$NAMS

Read the original article

Published by GlobeNewswire Pharma on May 7, 2026 11:00 AM

Read Original